Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine for ischemia-reperfusion injury in microsurgical breast reconstruction
2016-000623-73Phase 2Active
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lidocaine in ischemia-reperfusion injury (IRI) (2 arms), sponsored by Fundación de Investigación Biomédica Hospital Puerta de Hierro. Primary endpoint: MDA plasma levels at 12 hours after reperfusion. Started Jul 2016; status: active.
02
Drugs
lidocaine
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on 2016-000623-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000623-73.